InflaRx GmbH

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public, Subsidiary

Established: 2007-12-01

Employees: 11

Market Cap: -

Website: http://www.inflarx.com

Clinical Trials

Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa

Phase 2

Recruiting

Conditions: Chronic Urticaria, Idiopathic
Hidradenitis
Hidradenitis Suppurativa

Interventions: Drug: HS medium dose treatment
Drug: HS low dose treatment
Drug: HS high dose treatment
Drug: CSU high dose treatment
Drug: CSU non responders IgE - high dose treatment
Drug: CSU lower dose treatment

First Posted Date: 2024-08-15

Last Posted Date: 2025-01-08

Lead Sponsor: InflaRx GmbH

Target Recruit Count: 75

Registration Number: NCT06555328

Locations: 🇺🇸
ForCare Clinical Research, Tampa, Florida, United States
🇺🇸
MediSearch LLC, Saint Joseph, Missouri, United States

Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum

Phase 3

Recruiting

Conditions: Pyoderma Gangrenosum

Interventions: Drug: vilobelimab
Drug: Placebo

First Posted Date: 2023-07-27

Last Posted Date: 2024-12-20

Lead Sponsor: InflaRx GmbH

Target Recruit Count: 90

Registration Number: NCT05964413

Locations: 🇦🇺
Liverpool Hospital, Sydney, Australia
🇪🇸
Hospital Ramon y Cajal, Salamanca, Spain
🇺🇸
Aby´s New Generation Research, Inc, Hialeah, Florida, United States

and more 47 locations

Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

Phase 2

Terminated

Conditions: SCC - Squamous Cell Carcinoma of Skin

Interventions: Drug: IFX-1 + pembrolizumab combination therapy
Drug: IFX-1

First Posted Date: 2021-03-23

Last Posted Date: 2024-07-01

Lead Sponsor: InflaRx GmbH

Target Recruit Count: 25

Registration Number: NCT04812535

Locations: 🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
Inova Schar Cancer Institute, Fairfax, Virginia, United States

and more 22 locations

Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia

Phase 2

Completed

Conditions: Severe COVID-19 Pneumonia

Interventions: Drug: IFX-1 + BSC
Drug: BSC
Drug: IFX-1 + SOC
Drug: Placebo + SOC

First Posted Date: 2020-04-03

Last Posted Date: 2023-06-05

Lead Sponsor: InflaRx GmbH

Target Recruit Count: 399

Registration Number: NCT04333420

Locations: 🇲🇽
InflaRx Site #0502, Chihuahua, Mexico
🇫🇷
InflaRx Site #1004, Paris, France
🇩🇪
InflaRx Site #0202, Berlin, Germany

and more 45 locations

Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum

Phase 2

Completed

Conditions: Pyoderma Gangrenosum

Interventions: Drug: vilobelimab

First Posted Date: 2019-06-03

Last Posted Date: 2023-09-14

Lead Sponsor: InflaRx GmbH

Target Recruit Count: 19

Registration Number: NCT03971643

Locations: 🇺🇸
InflaRx Site #08, Miami, Florida, United States
🇨🇦
InflaRx Site #01, Richmond Hill, Ontario, Canada
🇺🇸
InflaRx Site #07, Sacramento, California, United States

and more 7 locations

Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.

Phase 2

Completed

Conditions: Granulomatosis With Polyangiitis (GPA)
Microscopic Polyangiitis (MPA)

Interventions: Drug: IFX-1
Drug: Placebo-IFX-1
Drug: Placebo-Glucocorticoid (Placebo-GC)
Drug: Glucocorticoid (GC)

First Posted Date: 2019-03-29

Last Posted Date: 2022-08-25

Lead Sponsor: InflaRx GmbH

Target Recruit Count: 57

Registration Number: NCT03895801

Locations: 🇬🇧
Clinical Site, Sheffield, United Kingdom
🇪🇸
Clinical site, Barcelona, Spain

Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA

Phase 2

Terminated

Conditions: Granulomatosis With Polyangiitis (GPA)
Microscopic Polyangiitis (MPA)

Interventions: Drug: IFX-1 high dose
Drug: Placebo
Drug: IFX-1 low dose

First Posted Date: 2018-10-19

Last Posted Date: 2022-05-26

Lead Sponsor: InflaRx GmbH

Target Recruit Count: 20

Registration Number: NCT03712345

Locations: 🇺🇸
Texas Health Resources, Dallas, Texas, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 35 locations

Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Phase 2

Completed

Conditions: Hidradenitis Suppurativa (HS)

Interventions: Drug: Placebo
Drug: IFX-1

First Posted Date: 2018-04-04

Last Posted Date: 2021-04-08

Lead Sponsor: InflaRx GmbH

Target Recruit Count: 179

Registration Number: NCT03487276

Locations: 🇵🇱
InflaRX Investigational Site, Łódź, Poland
🇺🇸
InflaRx Investigational Site, Goodlettsville, Tennessee, United States

Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa

Phase 2

Completed

Conditions: Hidradenitis Suppurativa

Interventions: Biological: IFX-1

First Posted Date: 2016-12-23

Last Posted Date: 2017-09-19

Lead Sponsor: InflaRx GmbH

Target Recruit Count: 12

Registration Number: NCT03001622

Locations: 🇬🇷
ATTIKON University Hospital, Athens, Greece

Studying Complement Inhibition in Complex Cardiac Surgery

Phase 2

Completed

Conditions: Systemic Inflammatory Response Syndrome
C.Surgical Procedure; Cardiac

Interventions: Biological: IFX-1
Biological: Placebo

First Posted Date: 2016-08-15

Last Posted Date: 2017-02-15

Lead Sponsor: InflaRx GmbH

Target Recruit Count: 116

Registration Number: NCT02866825

Locations: 🇩🇪
Study Site, Tuebingen, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy